We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“There is growing interest in earlier timing of TAVR. A key insight needed to better understand the risks and benefits of this approach is a deeper understanding of the outcomes of TAVR in asymptomatic or minimally symptomatic patients with severe aortic stenosis.”
“The data show we are likely not hurting patients by providing TAVR to minimally symptomatic patients, but that is not enough. We need to demonstrate we are actually helping them. There are good theoretical reasons for thinking we are: possibly a lower risk of sudden death, we can clear patients to exercise, and so on, but we can't claim we are helping them unless we can prove it.”
No takes yet. Share an insight, caveat, or question.
Huded et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: